Results for

Energy Prices Require Including Climate Externalities Act or the Energy PRICE Act This bill requires the Federal Energy Regulatory Commission (FERC) to direct electric utilities to take greenhouse gas emissions into account when they set their rates for the wholesale sale of electricity. Specifically, if FERC determines that the rates do not incorporate the cost of such emissions to public health, safety, or welfare, then FERC must find that the rates are unjust, unreasonable, unduly discriminatory, or preferential.

This bill requires the Department of Energy to establish a natural gas demand response pilot program that uses the latest demand response technology from the energy sector for natural gas to (1) reduce the cost of energy for consumers, (2) reduce market price volatility, (3) increase reliability of the energy system, and (4) achieve reductions in air emissions and other benefits.

Distributed Energy Demonstration Act of 2019 This bill establishes several renewable energy and energy efficiency grant programs. Specifically, the bill requires the Department of Energy (DOE) to establish grant programs for * advancing the integration and optimization of distributed energy resources (e.g., smaller power sources that can be aggregated to provide power, such as rooftop solar panels) into the electric energy grid; * demonstrating the use of household hot water heaters as energy storage resources; * advancing electric vehicle technologies; and * supporting the voluntary deployment of granular electricity pricing that is based upon the electricity's value at the time and location of the production or consumption of the electricity. In addition, the bill reauthorizes through FY2025 and revises the DOE grant program for smart grid investments.

Medicare Prescription Drug Price Negotiation Act of2019 This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. Current law prohibits the CMS from doing so.

Prescription Drug Pricing Dashboard Act This bill requires the Department of Health and Human Services to establish an online dashboard containing information about the prices and utilization of prescription drugs that are purchased by federal programs. The dashboard must include specified information, including spending per dosage, the number of drug recipients, and out-of-pocket costs. The dashboard must also highlight those drugs that have the highest spending and costs.

Tribal Energy Reauthorization Act This bill reauthorizes through FY2031 certain energy grant programs and otherwise revises the activities of the Office of Indian Energy Policy and Programs within the Department of Energy. Specifically, the office must * consider the fiscal ability of an Indian tribe, intertribal organization, or tribal energy development organization to meet cost-sharing requirements for energy projects; * give priority to partnering with state and local organizations when providing technical assistance to tribes; * designate a liaison to ensure that tribes are aware of federal grants and funding opportunities; and * develop an energy strategy for tribes in the Arctic to address climate change. The bill also authorizes the office to provide grants for providing or expanding electricity to the homes of members of tribes that are acquired, constructed, or improved with federal funds. Currently, such grants may only be used to provide electricity on Indian land.

Reducing the Cost of Energy Storage Act of 2019 This bill requires the Department of Energy (DOE)to research and develop ways to reduce the cost of energy storage, including by (1)facilitating innovation in the manner in which energy storage systems are conceived, designed, manufactured, installed, and used for various energy services; and (2)identifying, addressing, and reducing market barriers that limit energy storage adoption. As part of its research and development, DOE must pay special attention to energy storage needs and opportunities that are relatively underdeveloped and potentially transformative for the electric grid. DOE must develop cost targets (e.g., technology costs, installation costs, balance of services costs, and soft costs) for energy storage across all types of energy storage technology.

Insulin Price Reduction Act This bill prohibits health insurance plan issuers and pharmacy benefits managers (PBMs) from receiving rebates or discounts for insulin from manufacturers who certify that its current insulin list price has been reduced to an amount no greater than what the list price was for the same insulin on July 1, 2006. This restriction does not apply to discounts provided to insurance plan holders at retail sale or to flat-rate fees for service paid to PBMs. Further, insurance plans are prohibited from applying a deductible to insulin that has received such price certification. A manufacturer may certify insulin prices by submitting to the Department of Health and Human Services data about the list price of any insulin the manufacturer has produced since January 1, 2000, and by setting the current list price for an insulin product at the 2006 rate. To remain certified, a manufacturer may not increase the list price of insulin by more than the annual increase in the medical care consumer price index. A manufacturer may certify the price of an insulin product for which it did not have a list price in 2006 by reducing the list price of such insulin to the weighted average list price in 2006 of specified insulin categories. This bill also applies to Medicare prescription drug benefits. The bill sets the rebate for insulin under Medicaid based on the average manufacturer price of insulin during the last fiscal quarter of 2019, increasing by the medical care consumer price index thereafter.

Insulin Price Reduction Act This bill prohibits health insurance plan issuers and pharmacy benefits managers (PBMs) from receiving rebates or discounts for insulin from manufacturers who certify that its current insulin list price has been reduced to an amount no greater than what the list price was for the same insulin on July 1, 2006. This restriction does not apply to discounts provided to insurance plan holders at retail sale or to flat-rate fees for service paid to PBMs. Further, insurance plans are prohibited from applying a deductible to insulin that has received such price certification. A manufacturer may certify insulin prices by submitting to the Department of Health and Human Services data about the list price of any insulin the manufacturer has produced since January 1, 2000, and by setting the current list price for an insulin product at the 2006 rate. To remain certified, a manufacturer may not increase the list price of insulin by more than the annual increase in the medical care consumer price index. A manufacturer may certify the price of an insulin product for which it did not have a list price in 2006 by reducing the list price of such insulin to the weighted average list price in 2006 of specified insulin categories. This bill also applies to Medicare prescription drug benefits. The bill sets the rebate for insulin under Medicaid based on the average manufacturer price of insulin during the last fiscal quarter of 2019, increasing by the medical care consumer price index thereafter.

E. Cooper Brown Ocean Clean Energy Act of 2019 This bill allows an energy tax credit for the cost of ocean thermal energy equipment. The bill defines "ocean thermal energy equipment" as equipment that converts ocean thermal energy to usable energy or that uses ocean water as a thermal energy sink to cool a structure.

Clean Energy Standard Act of 2019 This bill addresses clean energy standards. Among other things, the bill * requires retail electricity suppliers to sell a certain quantity of clean electric energy; * establishes a federal clean energy credit trading program; * subjects retail electricity suppliers to civil penalties for noncompliance with requirements; * establishes a state energy efficiency, clean energy deployment, and electric bill reduction program; * requires the Department of Energy (DOE) to facilitate coordination between the federal clean energy program and state clean and renewable energy programs; * requires the National Academy of Sciences to periodically evaluate all aspects of the federal clean energy standard; and * directs DOE to establish a program for the research, development, demonstration, and deployment of clean energy technologies and portfolios.

Clean Energy Standard Act of 2019 This bill addresses clean energy standards. Among other things, the bill * requires retail electricity suppliers to sell a certain quantity of clean electric energy; * establishes a federal clean energy credit trading program; * subjects retail electricity suppliers to civil penalties for noncompliance with requirements; * establishes a state energy efficiency, clean energy deployment, and electric bill reduction program; * requires the Department of Energy (DOE) to facilitate coordination between the federal clean energy program and state clean and renewable energy programs; * requires the National Academy of Sciences to periodically evaluate all aspects of the federal clean energy standard; and * directs DOE to establish a program for the research, development, demonstration, and deployment of clean energy technologies and portfolios.

Consumer Access to Grid Information Act of 2020 This bill requires the Office of Energy Efficiency and Renewable Energy of the Department of Energy to establish a grant program for the creation of a cellular phone application (app). The app must allow the public to monitor power grids, including by enabling the public to view the demand and capacity of the energy grid, the types of energy sources that are serving the grid, and regional energy prices.

Unconscionable Pricing Act This bill makes it unlawful for any person to sell, rent, or lease an emergency supply at an unconscionable price during a federally-declared emergency. A price is unconscionable if (1) it exceeds 10% of the average price for the same or similar emergency supply during the 30 days before the emergency was declared, and (2) such price increase is not related to the reasonable costs incurred to sell or rent the supply. The bill grants the Federal Trade Commission and state attorneys general the authority to enforce compliance with the requirements of this bill.

Stop Price Gouging Act This bill imposes an excise tax on pharmaceutical companies that sell prescription drugs that are subject to price spikes that exceed the annual percentage increase in the Chained Consumer Price Index. For each taxable prescription drug, the excise tax ranges from 50% to 100% of price spike revenue received by the company, depending on the size of the price spike and including an adjustment for revenue that is due solely to an increase in the cost of the inputs necessary to manufacture the drug. Pharmaceutical companies must submit specified data regarding drug prices and revenue to the Inspector General (IG) of the Department of Health and Human Services (HHS), and the IG must submit an assessment of the data to the Internal Revenue Service. HHS, upon the recommendation of the IG, may exempt certain drugs from the excise tax if (1) a for-cause price increase exemption should apply; or (2) the drug has an average manufacturer price of not greater than $10 for a 30-day supply and is marketed by at least 3 other holders of applications approved under the Federal Food, Drug, and Cosmetic Act. The Government Accountability Office must examine (1) how drug manufacturers and health plans establish initial launch prices for newly approved drugs, and (2) alternative methods that have been proposed for setting the price of new drugs.

Stop Price Gouging Act This bill imposes an excise tax on pharmaceutical companies that sell prescription drugs that are subject to price spikes that exceed the annual percentage increase in the Chained Consumer Price Index. For each taxable prescription drug, the excise tax ranges from 50% to 100% of price spike revenue received by the company, depending on the size of the price spike and including an adjustment for revenue that is due solely to an increase in the cost of the inputs necessary to manufacture the drug. Pharmaceutical companies must submit specified data regarding drug prices and revenue to the Inspector General (IG) of the Department of Health and Human Services (HHS), and the IG must submit an assessment of the data to the Internal Revenue Service. HHS, upon the recommendation of the IG, may exempt certain drugs from the excise tax if (1) a for-cause price increase exemption should apply or; (2) the drug has an average manufacturer price of not greater than $10 for a 30-day supply and is marketed by at least 3 other holders of applications approved under the Federal Food, Drug, and Cosmetic Act. The Government Accountability Office must examine (1) how drug manufacturers and health plans establish initial launch prices for newly approved drugs, and (2) alternative methods that have been proposed for setting the price of new drugs.

Pandemic Response and Interstate Cost Equity Act or the PRICE Act This bill establishes the Federal Emergency Management Agency (FEMA) as the sole buyer, vendor, owner, and distributor of certain medical equipment obtained by the federal government in the event of a national health emergency and establishes a process for the pricing and distribution of such equipment. Specifically, in the event of such an emergency, the Department of Health and Human Services shall assess available medical equipment and FEMA shall (1) become the sole owner and distributor of medical equipment obtained by the federal government for which the prevailing market price exceeds the fair market price by more than 15%, (2) contract with all persons capable of producing such equipment to produce such equipment, and (3) establish a price for such equipment and sell or otherwise distribute the equipment to the states or to persons that request it. The bill establishes in Congress a Joint Committee on Defense Production. *

Pandemic Response and Interstate Cost Equity Act or the PRICE Act This bill establishes the Federal Emergency Management Agency (FEMA) as the sole buyer, vendor, owner, and distributor of certain medical equipment obtained by the federal government in the event of a national health emergency and establishes a process for the pricing and distribution of such equipment. Specifically, in the event of such an emergency, the Department of Health and Human Services shall assess available medical equipment and FEMA shall (1) become the sole owner and distributor of medical equipment obtained by the federal government for which the prevailing market price exceeds the fair market price by more than 15%, (2) contract with all persons capable of producing such equipment to produce such equipment, and (3) establish a price for such equipment and sell or otherwise distribute the equipment to the states or to persons that request it. The bill establishes in Congress a Joint Committee on Defense Production. *

Combatting Unreasonable Rises and Excessively High Drug Prices Act or the CURE High Drug Prices Act This bill prohibits price gouging by manufacturers of prescription drugs (including a combination of a drug, device, or biological product) that are covered by a federal health care program. The bill specifies percentage increases in price at which price gouging is presumed.

Combatting Unreasonable Rises and Excessively High Drug Prices Act or the CURE High Drug Prices Act This bill prohibits price gouging by manufacturers of prescription drugs (including a combination of a drug, device, or biological product) that are covered by a federal health care program. The bill specifies percentage increases in price at which price gouging is presumed.

End Price Gouging for Medications Act This bill requires the Department of Health and Human Services (HHS) to set maximum prices for prescription drugs under specified federal health programs. Specifically, HHS must establish reference prices based on certain factors, including drug prices in listed countries. Retail prices of covered drugs under specified federal health programs (e.g., Medicare and Medicaid) may not exceed the established reference prices. Drugs must also be available at such prices to uninsured individuals and to individuals with private health insurance.

End Price Gouging for Medications Act This bill requires the Department of Health and Human Services (HHS) to set maximum prices for prescription drugs under specified federal health programs. Specifically, HHS must establish reference prices based on certain factors, including drug prices in listed countries. Retail prices of covered drugs under specified federal health programs (e.g., Medicare and Medicaid) may not exceed the established reference prices. Drugs must also be available at such prices to uninsured individuals and to individuals with private health insurance.

Net Price Calculator Improvement Act This bill establishes requirements concerning the information that must be provided to prospective students about the cost of an institution of higher education (IHE). Specifically, the bill establishes the minimum requirements for the net price calculator that an IHE must include on its website. An IHE's net price is the average yearly price actually charged to first-time, full-time undergraduate students receiving student aid at the school after deducting such aid. It authorizes the Department of Education to develop a universal net price calculator that enables users to answer one set of questions and receive net prices for several IHEs and compare those prices.

Net Price Calculator Improvement Act This bill establishes requirements concerning the information that must be provided to prospective students about the cost of an institution of higher education (IHE). Specifically, the bill establishes the minimum requirements for the net price calculator that an IHE must include on its website. An IHE's net price is the average yearly price actually charged to first-time, full-time undergraduate students receiving student aid at the school after deducting such aid. It authorizes the Department of Education to develop a universal net price calculator that enables users to answer one set of questions and receive net prices for several IHEs and compare those prices.